华熙生物，股东拟减持

Core Viewpoint - China Life Chengda plans to reduce its holdings in Huaxi Biological shares by up to 9.6336 million shares, representing no more than 2% of Huaxi Biological's total share capital [2][5]. Group 1: Shareholding and Reduction Plan - China Life Chengda, a private equity investment company under China Life, currently holds 28.9365 million shares of Huaxi Biological, accounting for 6.01% of the total share capital, making it the second-largest shareholder [5]. - The planned reduction will occur through centralized bidding and block trading, with a maximum of 1% of shares to be sold via each method [2]. - The reduction period is set for three months, starting from 15 trading days after the announcement, specifically from November 26, 2025, to February 23, 2026 [2]. Group 2: Recent Performance and Previous Reductions - Huaxi Biological's performance has been declining, with a reported revenue of 3.163 billion yuan for the first three quarters of 2025, a year-on-year decrease of 18.36%, and a net profit of 252 million yuan, down 30.29% year-on-year [6]. - Prior to this announcement, China Life Chengda had already reduced its holdings by 5.4968 million shares between October 31, 2024, and November 12, 2024, at a price range of 59.28 to 68.1 yuan per share, which represented a reduction of 1.14% [6]. - As of November 4, 2025, Huaxi Biological's stock price closed at 52.05 yuan per share, giving it a market capitalization of 25.1 billion yuan [9].